Despite studies on immunomodulators, BsAbs, TanCAR, bi-specific CAR-T cells, and TME to improve the therapeutic status of HER2-targeted CAR-T cells, a recognized effective approach to improve HER2-targeted CAR-T cells for HER-2-positive breast cancer is lacking. This evidence concerns the gene ERBB2 and breast cancer.